Replies to post #23460 on Cytodyn Inc (CYDY)

[misiu143]

Finesand - most of medicine is given to many patients with different doses .

IMO , the most important here is that we don’t see more side effects with higher dose .

I believe about 56% of patients did very well on P2 extension study .
This was a time when tests for CCR5 were not very accurate and dose was 350 mg .

Now tests are much better so patients selection is much better .

Also we know about different density of CCR5 , and dose of medicine is adjusted to 525 mg ,

I will expect big improvement in patients response ,
But of course mono study will prove one or another way .

Again the most important is that patients tolerating higher dose .

Not one serious side effect was reported by a company so far.